Leading scientists summarize the latest findings on signal transduction and cell cycle regulation and describe the effort to design and synthesize inhibiting molecules, as well as to evaluate their biochemical and biological activities. They review the relevant cell surface receptors, their ligands, and their downstream pathways. Also examined are the latest findings on the components of novel signaling networks controlling the activity of nuclear transcription factors and cell cycle regulatory molecules. Cutting-edge and highly suggestive, Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases presents a wealth of information on the emerging principles of the field, as well as an invaluable guide for all experimental and clinical investigators of cell regulation and its rapidly emerging pharmacological opportunities today.

Klappentext

The recent dramatic expansion of our knowledge about how cell surface receptors transmit signals to the nucleus, together with the identification of key signaling and cell-cycle-regulating molecules, has provided a major opportunity to search for novel targets for therapeutic intervention in many diseases. In Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases, leading scientists summarize this knowledge and describe the effort to design and synthesize inhibiting molecules, as well as to evaluate their biochemical and biological activities. They review the relevant cell surface receptors, their ligands, and their downstream pathways. Also examined are the latest findings on the components of novel signaling networks controlling the activity of nuclear transcription factors and cell cycle regulatory molecules.
Rich in cutting-edge insights and authoritative critical analysis, Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases presents a wealth of information on the emerging principles of the field, as well as an invaluable guide for all experimental and clinical investigators of cell regulation and its rapidly emerging pharmacological opportunities today.

Inhalt
1 Integrin Signaling.- 2 Signal Transduction Through Tyrosine Kinase Growth Factor Receptors.- 3 Signaling from TGF-? Receptors.- 4 The Wnt Signal Transduction Pathway.- 5 Signaling from G-Protein-Coupled Receptors to the Nucleus.- 6 Proximal Events in T-Cell Activation.- 7 Signal Transduction from the High Affinity IgE Receptor.- 8 Signaling Through Fas (CD95, APO-1) and Related Death Receptors.- 9 Signal Transduction to the Nucleus by MAP Kinase.- 10 The Regulation of MAP Kinase Pathways by MAP Kinase Phosphatases.- 11 Control of MAPK Signaling by Ste20- and Stel 1-Like Kinases.- 12 Ras Signaling and Transformation.- 13 Signaling Pathways Controlled by Rho Family GTP-Binding Proteins.- 14 PI3-Kinases: Role in Signal Transduction.- 15 PI3K-Related Kinases: Roles in Cell-Cycle Regulation and DNA Damage Responses.- 16 Integrative Signaling Through c-Abl: A Tyrosine Kinase with Nuclear and Cytoplasmic Functions.- 17 Src: A Model for Regulation of Intracellular Signaling Molecules.- 18 Inhibitors of Protein Kinase C and Related Receptors for the Lipophilic Second Messenger sn-1,2-Diacylglycerol.- 19 Reactive Oxygen Species in Proliferative Signaling.- 20 Sphingolipid Metabolites in Signal Transduction.- 21 The Jak/Stat Signaling Cascade: Its Role in the Biological Effects of Interferons.- 22 Regulation of Cell Growth and Death by p53.- 23 Regulation of NF-?B Function: Novel Molecular Targets for Pharmacological Intervention.- 24 Using ProteinInteraction Domains to Manipulate Signaling Pathways.- 25 Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents.- 26 A Pharmacological Approach to the MAP Kinase Cascade.- 27 Specific Inhibitors of p38 MAP Kinase.- 28 Farnesyltransferase Inhibitors: Anti-Ras or Anticancer Drugs?.- 29 Targeted p53 Gene Therapy-MediatedRadiosensitization and Chemosensitization.- 30 Treatment of p53-Deficient Cancers by Adenovirus E1B-Region Mutants: From Basic Research to the Clinic.- 31 The Cell Cycle Inhibitor p27 as a Prognostic Marker in Human Tumors and a Novel Target for Therapeutic Intervention.- 32 Chemical Cyclin-Dependent Kinase Inhibitors: Therapeutic Implications.